Reduced Dose Intensity FOLFOX-4 as First Line Palliative Chemotherapy in Elderly Patients with Advanced Colorectal Cancer.
10.3346/jkms.2005.20.5.806
- Author:
Jee Hyun KIM
1
;
Do Youn OH
;
Yu Jung KIM
;
Sae Won HAN
;
In Sil CHOI
;
Dong Wan KIM
;
Seock Ah IM
;
Tae You KIM
;
Jong Seok LEE
;
Dae Seog HEO
;
Yung Jue BANG
;
Noe Kyeong KIM
Author Information
1. Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea. moisa@snu.ac.kr
- Publication Type:Original Article ; Research Support, Non-U.S. Gov't
- Keywords:
Aged;
Colorectal Neoplasms;
Antineoplastic Combined Chemotherapy Protocols;
Folfox protocol
- MeSH:
Aged;
Aged, 80 and over;
Antineoplastic Agents/administration and dosage;
Antineoplastic Combined Chemotherapy Protocols/*administration and dosage;
Colorectal Neoplasms/*drug therapy/*mortality;
Disease-Free Survival;
Dose-Response Relationship, Drug;
Female;
Fluorouracil/administration and dosage;
Humans;
Incidence;
Korea/epidemiology;
Leucovorin/administration and dosage;
Male;
Organoplatinum Compounds/administration and dosage;
Palliative Care/*statistics and numerical data;
Research Support, Non-U.S. Gov't;
Risk Assessment/*methods;
Risk Factors;
Survival Analysis;
Survival Rate;
Terminal Care/*statistics and numerical data;
Treatment Outcome
- From:Journal of Korean Medical Science
2005;20(5):806-810
- CountryRepublic of Korea
- Language:English
-
Abstract:
To evaluate the toxicity and efficacy of a reduced dose intensity (mini-) FOLFOX-4 regimen as a first-line palliative chemotherapy in elderly patients (> or =70 yr of age) with advanced colorectal cancer, data from prospective databases at Seoul National University Bundang Hospital and Seoul Municipal Boramae Hospital were analyzed. A total of 20 patients were enrolled between January 2001 and August 2004, and were treated with oxaliplatin 65 mg/m2 on day 1, and with 2-hr infusions of leucovorin 150 mg/m2 followed by a 5-FU bolus (300 mg/m2) and 22-hr continuous infusions (450 mg/m2) for 2 consecutive days every 2 weeks until progression, unacceptable toxicity or patient refusal. Sixteen patients were evaluable for response with an overall response rate of 43.8%. Median progression-free survival was 4.8 months (95% CI: 3.0-6.7) and overall survival was 13.5 months (95% CI: 11.1-16.0). The main side effects were anemia and neutropenia, which were observed in 20.8% and 17.7%, respectively, of the total cycles administered. There were no grade 4 toxicities and only one patient suffered from febrile neutropenia. No grade 3 toxicities occurred except for anemia (5.2%) and vomiting (1.0%). In conclusion, the mini-FOLFOX-4 regimen was found to be well tolerated with acceptable toxicity, and to provide a benefit for elderly patients with colorectal cancer.
